跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

Y0000543

Oxazepam for peak identification

European Pharmacopoeia (EP) Reference Standard

别名:

Oxazepam, 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-1,4(2H)-benzodiazepin-2-one

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C15H11ClN2O2
CAS号:
604-75-1
分子量:
286.71
MDL编号:
MFCD00057903
UNSPSC代码:
41116107
PubChem化学物质编号:
329831008
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

oxazepam

制造商/商品名称

EDQM

药品控制

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

OC1N=C(c2ccccc2)c3cc(Cl)ccc3NC1=O

InChI

1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)

InChI key

ADIMAYPTOBDMTL-UHFFFAOYSA-N

基因信息

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Oxazepam for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

Anxiolytic; ligand for the GABAA receptor benzodiazepine modulatory site.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazardExclamation mark
GHS08,GHS07

警示用语：

Warning

危险声明

H336,H351

危险分类

Carc. 2 - STOT SE 3

靶器官

Central nervous system

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Joel Hellrup et al.
International journal of pharmaceutics, 409(1-2), 96-103 (2011-03-02)
The aim of this study was to explore how pharmaceutical micro-sized filler particles affect the amorphous stability of sucrose in sucrose/filler particle composites produced by freeze-drying. Focus was put on the filler particles' properties crystallinity, hygroscopicity, hydrophobicity, and surface area
Pharmacokinetics in clinical medicine: oxazepam versus other benzodiazepines.
D J Greenblatt et al.
Diseases of the nervous system, 36(5 Pt. 2), 6-13 (1975-05-01)
Katarina Gospic et al.
PLoS biology, 9(5), e1001054-e1001054 (2011-05-12)
Imaging studies have revealed a putative neural account of emotional bias in decision making. However, it has been difficult in previous studies to identify the causal role of the different sub-regions involved in decision making. The Ultimatum Game (UG) is
M H Lader
Acta psychiatrica Scandinavica. Supplementum, (274)(274), 89-93 (1978-01-01)
The benzodiazepines have been available now for about 15 years but new aspects of their actions are being elucidated all the time. Oxazepam has a short half-life and inactive metabolites and therefore differs from most other benzodiazepines. Some aspects of
Maarten Charles J Franck et al.
Patient education and counseling, 83(3), 411-416 (2011-05-31)
We developed a semi-automated leaflet optimizer (ABOP) to improve the readability of Dutch patient information leaflets (PILs). Our aim was to assess whether or not revisions made with ABOP have an effect on traceability and comprehension of PIL information. Two
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门